TY  - JOUR
AU  - Herbert, Carly
AU  - Kheterpal, Vik
AU  - Suvarna, Thejas
AU  - Broach, John
AU  - Marquez, Juan Luis
AU  - Gerber, Ben
AU  - Schrader, Summer
AU  - Nowak, Christopher
AU  - Harman, Emma
AU  - Heetderks, William
AU  - Fahey, Nisha
AU  - Orvek, Elizabeth
AU  - Lazar, Peter
AU  - Ferranto, Julia
AU  - Noorishirazi, Kamran
AU  - Valpady, Shivakumar
AU  - Shi, Qiming
AU  - Lin, Honghuang
AU  - Marvel, Kathryn
AU  - Gibson, Laura
AU  - Barton, Bruce
AU  - Lemon, Stephenie
AU  - Hafer, Nathaniel
AU  - McManus, David
AU  - Soni, Apurv
PY  - 2022
DA  - 2022/6/16
TI  - Design and Preliminary Findings of Adherence to the Self-Testing for Our Protection From COVID-19 (STOP COVID-19) Risk-Based Testing Protocol: Prospective Digital Study
JO  - JMIR Form Res
SP  - e38113
VL  - 6
IS  - 6
KW  - COVID-19
KW  - rapid antigen tests
KW  - COVID-19 testing
KW  - infectious disease
KW  - disease spread
KW  - prevention
KW  - coronavirus
KW  - adherence
KW  - reporting
KW  - mHealth
KW  - health application
KW  - mobile health
KW  - digital health
KW  - public health
KW  - surveillance
KW  - health care
KW  - smartphone app
KW  - vaccination
KW  - digital surveillance
AB  - Background: Serial testing for SARS-CoV-2 is recommended to reduce spread of the virus; however, little is known about adherence to recommended testing schedules and reporting practices to health departments. Objective: The Self-Testing for Our Protection from COVID-19 (STOP COVID-19) study aims to examine adherence to a risk-based COVID-19 testing strategy using rapid antigen tests and reporting of test results to health departments. Methods: STOP COVID-19 is a 12-week digital study, facilitated using a smartphone app for testing assistance and reporting. We are recruiting 20,000 participants throughout the United States. Participants are stratified into high- and low-risk groups based on history of COVID-19 infection and vaccination status. High-risk participants are instructed to perform twice-weekly testing for COVID-19 using rapid antigen tests, while low-risk participants test only in the case of symptoms or exposure to COVID-19. All participants complete COVID-19 surveillance surveys, and rapid antigen results are recorded within the smartphone app. Primary outcomes include participant adherence to a risk-based serial testing protocol and percentage of rapid tests reported to health departments. Results: As of February 2022, 3496 participants have enrolled, including 1083 high-risk participants. Out of 13,730 tests completed, participants have reported 13,480 (98.18%, 95% CI 97.9%-98.4%) results to state public health departments with full personal identifying information or anonymously. Among 622 high-risk participants who finished the study period, 35.9% showed high adherence to the study testing protocol. Participants with high adherence reported a higher percentage of test results to the state health department with full identifying information than those in the moderate- or low-adherence groups (high: 71.7%, 95% CI 70.3%-73.1%; moderate: 68.3%, 95% CI 66.0%-70.5%; low: 63.1%, 59.5%-66.6%). Conclusions: Preliminary results from the STOP COVID-19 study provide important insights into rapid antigen test reporting and usage, and can thus inform the use of rapid testing interventions for COVID-19 surveillance. 
SN  - 2561-326X
UR  - https://formative.jmir.org/2022/6/e38113
UR  - https://doi.org/10.2196/38113
UR  - http://www.ncbi.nlm.nih.gov/pubmed/35649180
DO  - 10.2196/38113
ID  - info:doi/10.2196/38113
ER  -